LifeMine Therapeutics
LifeMine Therapeutics is revolutionizing drug discovery by mining genetically-encoded small molecules from the biosphere, utilizing an advanced AI- and genomically-enabled platform.
Company Overview
LifeMine Therapeutics is an innovative company focused on reinventing drug discovery. By mining genetically-encoded small molecules (GEMs) from the biosphere, they have developed a cutting-edge, AI- and genomically-enabled drug discovery engine. Their approach is designed to yield naturally inspired drugs that operate in unexpected ways. Headquartered at Cambridge Discovery Park, Cambridge, MA, LifeMine Therapeutics also maintains sites in Gloucester, MA, and Basel, Switzerland.
Drug Discovery Engine
LifeMine Therapeutics employs an integrated, evolution-derived, AI- and genomically-enabled drug discovery engine. This engine facilitates the rapid discovery of small molecule therapeutic solutions by utilizing fungi as 'avatars'. The platform includes high-throughput microbiology, data science, machine learning, genome engineering, and automation technologies. Additionally, it integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation.
Fungal Genome Repository
LifeMine Therapeutics boasts a fully curated fungal genome repository of unprecedented scale. This resource is central to their drug discovery process, functioning as a springboard for rapid, predictable, and scalable discovery of naturally inspired drugs. By leveraging their extensive repository, LifeMine can uncover small molecule drugs that target human diseases in novel and precise ways.
Research Locations
LifeMine Therapeutics operates from multiple strategic locations. Their headquarters are situated at Cambridge Discovery Park, 30 Acorn Park Drive, Cambridge, MA 02140. Additionally, they have a site in Gloucester, MA at 417 Main St, 2nd Floor, and an international presence in Basel, Switzerland at Klybeckstrasse 191, WKL 136, 4057 Basel. These locations support their comprehensive research and development activities.
Financial Milestones and Partnerships
Since its inception, LifeMine Therapeutics has achieved significant financial milestones. The company launched with a $55 million Series A financing. Subsequent funding rounds included a $50 million Series B and a $175 million Series C financing. LifeMine Therapeutics has also formed strategic alliances, including a notable drug discovery and development partnership with GSK. In recognition of its impact in biotechnology, the company was named one of the 'Fierce 15' Biotech Companies of 2022 by Fierce Biotech.